openPR Logo
Press release

Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Merck, Taiho Pharma, Sichuan Kelun-Biotech, ALX Oncology, AskGene Pharma, Inc., Akeso

09-27-2024 04:30 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Gastroesophageal Adenocarcinoma Market to Show Remarkable

The Key Gastroesophageal Adenocarcinoma Companies in the market include - Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.

DelveInsight's "Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Gastroesophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroesophageal Adenocarcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Adenocarcinoma Market Forecast [https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Gastroesophageal Adenocarcinoma Market Report:

*
The Gastroesophageal Adenocarcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In June 2024, Arcus Biosciences has completed patient enrollment for the Phase III STAR-221 clinical trial, which evaluates the combination of domvanalimab and zimberelimab with chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (upper GI cancers). Domvanalimab is an Fc-silent anti-TIGIT antibody, while zimberelimab is an anti-PD-1 monoclonal antibody. Both therapies are currently under investigation.

*
In 2023, the total number of incident cases of gastroesophageal adenocarcinoma exceeded 220,000 across the 7MM.

*
In 2023, Japan recorded the highest number of incident cases of gastroesophageal adenocarcinoma among the 7MM.

*
In the US, Stage IV had the highest number of incident cases of gastroesophageal adenocarcinoma, whereas Japan reported the most cases in Stage I.

*
Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.

*
Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others

*
The Gastroesophageal Adenocarcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Adenocarcinoma pipeline products will significantly revolutionize the Gastroesophageal Adenocarcinoma market dynamics.

Gastroesophageal Adenocarcinoma Overview

Gastroesophageal adenocarcinoma is a type of cancer that arises from the glandular cells lining the esophagus and the stomach. It is characterized by the abnormal growth of these cells, which can lead to the formation of tumors. This cancer often develops at the junction of the esophagus and stomach (gastroesophageal junction) and is associated with risk factors such as obesity, gastroesophageal reflux disease (GERD), smoking, and a diet low in fruits and vegetables. Symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn. Diagnosis typically involves imaging tests, endoscopy, and biopsy. Treatment options may include surgery, chemotherapy, radiation therapy, or targeted therapies, depending on the cancer's stage and the patient's overall health.

Get a Free sample for the Gastroesophageal Adenocarcinoma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/gastroesophageal-adenocarcinoma-market [https://www.delveinsight.com/report-store/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastroesophageal Adenocarcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroesophageal Adenocarcinoma Epidemiology Segmentation:

The Gastroesophageal Adenocarcinoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Gastroesophageal Adenocarcinoma

*
Prevalent Cases of Gastroesophageal Adenocarcinoma by severity

*
Gender-specific Prevalence of Gastroesophageal Adenocarcinoma

*
Diagnosed Cases of Episodic and Chronic Gastroesophageal Adenocarcinoma

Download the report to understand which factors are driving Gastroesophageal Adenocarcinoma epidemiology trends @ Gastroesophageal Adenocarcinoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastroesophageal Adenocarcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Adenocarcinoma market or expected to get launched during the study period. The analysis covers Gastroesophageal Adenocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroesophageal Adenocarcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroesophageal Adenocarcinoma Therapies and Key Companies

*
KEYTRUDA (pembrolizumab): Merck

*
LONSURF (trifluridine/ tipiracil): Taiho Pharmaceuticals

*
Sacituzumab Tirumotecan (MK-2870): Merck/Sichuan Kelun-Biotech

*
Evorpacept (ALX148): ALX Oncology

*
Paclitaxel: Canadian Cancer Trials Group

*
Trifluridine-Tipiracil: Merck Sharp & Dohme LLC

*
ASKB589: AskGene Pharma, Inc.

*
AK104: Akeso

*
OBP-301: Weill Medical College

*
tucatinib: Seagen Inc.

*
Docetaxel for injection (Albumin-bound): CSPC ZhongQi Pharmaceutical

*
Zanidatamab: Jazz Pharmaceuticals

*
Trastuzumab deruxtecan: Daiichi Sankyo

*
Capecitabine: RemeGen Co., Ltd.

*
Infigratinib: LianBio LLC

*
Atezolizumab: Hoffmann-La Roche

*
Bemarituzumab: Amgen

*
PT886: Phanes Therapeutics

Discover more about therapies set to grab major Gastroesophageal Adenocarcinoma market share @ Gastroesophageal Adenocarcinoma Treatment Landscape [https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastroesophageal Adenocarcinoma Market Drivers

*
Increasing Incidence Rates

*
Advancements in Treatment

*
Improved Diagnostic Techniques

*
Aging Population

*
Rising Awareness

*
Clinical Trials and Research

Gastroesophageal Adenocarcinoma Market Barriers

*
High Treatment Costs

*
Limited Early Detection

*
Side Effects of Treatment

*
Drug Resistance

*
Regulatory Hurdles

*
Geographical Disparities

Scope of the Gastroesophageal Adenocarcinoma Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others

*
Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others

*
Gastroesophageal Adenocarcinoma Therapeutic Assessment: Gastroesophageal Adenocarcinoma current marketed and Gastroesophageal Adenocarcinoma emerging therapies

*
Gastroesophageal Adenocarcinoma Market Dynamics: Gastroesophageal Adenocarcinoma market drivers and Gastroesophageal Adenocarcinoma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Gastroesophageal Adenocarcinoma Unmet Needs, KOL's views, Analyst's views, Gastroesophageal Adenocarcinoma Market Access and Reimbursement

To know more about Gastroesophageal Adenocarcinoma companies working in the treatment market, visit @ Gastroesophageal Adenocarcinoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Gastroesophageal Adenocarcinoma Market Report Introduction

2. Executive Summary for Gastroesophageal Adenocarcinoma

3. SWOT analysis of Gastroesophageal Adenocarcinoma

4. Gastroesophageal Adenocarcinoma Patient Share (%) Overview at a Glance

5. Gastroesophageal Adenocarcinoma Market Overview at a Glance

6. Gastroesophageal Adenocarcinoma Disease Background and Overview

7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroesophageal Adenocarcinoma

9. Gastroesophageal Adenocarcinoma Current Treatment and Medical Practices

10. Gastroesophageal Adenocarcinoma Unmet Needs

11. Gastroesophageal Adenocarcinoma Emerging Therapies

12. Gastroesophageal Adenocarcinoma Market Outlook

13. Country-Wise Gastroesophageal Adenocarcinoma Market Analysis (2020-2034)

14. Gastroesophageal Adenocarcinoma Market Access and Reimbursement of Therapies

15. Gastroesophageal Adenocarcinoma Market Drivers

16. Gastroesophageal Adenocarcinoma Market Barriers

17. Gastroesophageal Adenocarcinoma Appendix

18. Gastroesophageal Adenocarcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastroesophageal-adenocarcinoma-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-merck-taiho-pharma-sichuan-kelunbiotech-alx-oncology-askgene-pharma-inc-akeso]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Merck, Taiho Pharma, Sichuan Kelun-Biotech, ALX Oncology, AskGene Pharma, Inc., Akeso here

News-ID: 3670940 • Views:

More Releases from ABNewswire

Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance Repair with Extended Service Hours
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients. Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue Massage Approach
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief. Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shortage
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access. The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair Launches 24/7 Emergency Response
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise. Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical

All 5 Releases


More Releases for Gastroesophageal

Gastroesophageal Reflux Disease (GERD) Devices Market Insights and Future Outloo …
Introduction Gastroesophageal Reflux Disease (GERD) is a chronic condition where stomach contents flow back into the esophagus, causing symptoms such as heartburn, regurgitation, chest pain, and, in severe cases, esophagitis or Barrett's esophagus. While medications like proton pump inhibitors (PPIs) are widely used for management, a growing number of patients experience refractory GERD, where pharmacological treatments fail to provide relief. This has accelerated demand for GERD devices, which include endoscopic therapies, implantable
Gastroesophageal Reflux Disease Therapeutics Market Heartburn Relief on the Rise …
Gastroesophageal Reflux Disease Therapeutics Market to reach over USD 6.06 billion by the year 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-kinetic agents)- Market Outlook And Industry Analysis 2031" The global Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease Device Market Size 2024 to 2031.
Market Overview and Report Coverage Gastroesophageal Reflux Disease (GERD) devices are medical devices used to treat GERD, a chronic disease characterized by the reflux of stomach acid into the esophagus. These devices include sphincter augmentation devices, magnetic sphincter augmentation devices, and radiofrequency ablation devices, among others. They are designed to help alleviate symptoms of GERD and improve the quality of life for patients. The Gastroesophageal Reflux Disease Device Market is
Gastroesophageal Reflux Disease Therapeutics Market: Trends and Projections -203 …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033 The Business Research Company presents an extensive market research report on the Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments. Furthermore, the report highlights on emerging trends, significant drivers, challenges,
Gastroesophageal Junction Adenocarcinoma Therapeutics Market - Revolutionizing C …
Newark, New Castle, USA: The "Gastroesophageal Junction Adenocarcinoma Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Gastroesophageal Junction Adenocarcinoma Therapeutics Market: https://www.growthplusreports.com/report/gastroesophageal-junction-adenocarcinoma-therapeutics-market/8809 This latest report researches the
Gastroesophageal Reflux Disease Therapeutics Market
As per the research conducted by GME, the Global Gastroesophageal Reflux Disease Therapeutics Market will grow with a CAGR value of 4.1%. During the forecasted timeframe, the gastroesophageal reflux disease market is likely to be sustained by a rise in the number of patients being treated for gastroesophageal reflux disease and long-term anti-reflux conservation therapy. Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC